22:56 , Apr 20, 2018 |  BioCentury  |  Emerging Company Profile

Clear for Landos

Landos Biopharma Inc. is developing a first-in-class LANCL2 agonist designed to provide improved convenience, efficacy and safety over standard-of-care therapies for inflammatory bowel disease (IBD), including moderate to severe Crohn’s disease (CD) and ulcerative colitis...
07:00 , Jun 4, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: NLR family member X1 (NLRX1)

Pulmonary disease INDICATION: Chronic obstructive pulmonary disease (COPD) Studies in mice and patient samples suggest promoting NLRX1 could help treat cigarette smoke-induced COPD. Levels of NLRX1 mRNA were lower in lung tissue samples from patients with COPD...
07:00 , Jul 14, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Infectious disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease Influenza virus NLR family member X1 (NLRX1) In vitro and mouse studies suggest activating...